Biogen Pharmachem Industries Limited has announced its financial results for the quarter and half-year ended September 30, 2026. For the second quarter, the company reported a profit after tax of ₹25.73 lakh. The total comprehensive income for the period also stood at ₹25.73 lakh. The board meeting where these results were considered and approved was held on November 3, 2026.
Biogen Pharmachem Industries Announces Q2 FY27 Financial Results
Biogen Pharmachem Industries Limited has released its unaudited financial results for the quarter and half-year ended September 30, 2026. The company’s Board of Directors approved these results during a meeting held on November 3, 2026.
Financial Performance – Q2 FY27
For the quarter ended September 30, 2026, Biogen Pharmachem Industries reported a total income from operations of ₹28.33 lakh. The expenses for the quarter amounted to ₹2.61 lakh, leading to a profit before tax of ₹25.73 lakh. After accounting for tax expenses, the net profit after tax for the quarter stood at ₹25.73 lakh. The total comprehensive income for the quarter was also ₹25.73 lakh.
Financial Performance – Half Year Ended September 30, 2026
For the six months ended September 30, 2026, the company’s total income from operations was ₹72.67 lakh. Total expenses for the half-year were ₹24.80 lakh, resulting in a profit before tax of ₹47.87 lakh. The net profit after tax for the half-year stood at ₹47.87 lakh, with total comprehensive income at the same figure.
Balance Sheet Highlights
As of September 30, 2026, the company’s total assets were reported at ₹9,975.57 lakh. Equity share capital stood at ₹10,530.37 lakh, while other equity was recorded as (₹573.79) lakh, resulting in total shareholders’ funds of ₹9,956.58 lakh. Non-current liabilities were ₹9.73 lakh, and current liabilities amounted to ₹9.27 lakh.
Source: BSE
